

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum- based chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
No.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
Yes. The company noted that the risk of BRCA mutation is higher for people from Ashkenazi Jewish background, and that people who do not identify as female may have ovarian cancer. Patient organisations also noted some people may have difficulty undergoing genetic testing for BRCA mutation due to religious and social beliefs. The committee acknowledged the issues raised and agreed that its recommendation would apply to all people regardless of their family background or belief. Its recommendation would not have a different impact on people protected by the equality legislation than on the wider population and olaparib will be available for all people.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, Section 3.16.

Approved by Associate Director (name):Janet Robertson.....

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Issue date: February 2024

Date: 21 February 2024